Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

1. Vaccination in individuals with Down syndrome: immune vulnerability, safety, efficacy and opportunities.NPJ vaccines · 2026
   Review
2. Cost-Effectiveness and Budget Impact Analysis of the Trivalent Adjuvanted Influenza Vaccine in People over 50 Years of Age for Argentina.Vaccines · 2026
   Article
3. Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019-2020 US Influenza Season.Open forum infectious diseases · 2024
   Article
4. Rollout of the 2022/2023 Seasonal Influenza Vaccination and Correlates of the Use of Enhanced Vaccines among Italian Adults.Vaccines · 2023
   Article
5. Novel Influenza Vaccines: From Research and Development (R&D) Challenges to Regulatory Responses.Vaccines · 2023
   Review
6. Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine Among Adults ≥65 Years.Open forum infectious diseases · 2023
   Article
7. [Efficacy, effectiveness and safety of the adjuvanted influenza vaccine in the population aged 65 or over].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
   Review
8. Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States.Vaccines · 2022
   Review
9. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.Vaccines · 2022
   Article
10. Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research.Vaccines · 2022
    Article
11. Influenza Viruses and Vaccines: The Role of Vaccine Effectiveness Studies for Evaluation of the Benefits of Influenza Vaccines.Vaccines · 2022
    Review
12. Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults.Frontiers in aging · 2022
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as